Stock Ratings / Health Care / BGLC / insiders

ADVB (32) ACON (24) AMS (29) SERA (40) ⌘ Pro Terminal →

BioNexus Gene Lab Corp (BGLC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are BGLC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BGLC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$0.98 -7.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioNexus Gene Lab Corp (BGLC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGLC)Realized 20D OHLCV Swing Band: ±10.6%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BGLC Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BGLC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BGLC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGLC)

✓Walkthrough of BGLC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BGLC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.33%▼ SUPPORT BREAKDOWN

2026-10-30O $0.93H $0.98L $0.88C $0.98VOL 7.5K

RES: $0.98SUP: $1.13SMA50: $1.35SMA200: $1.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BGLC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BGLC Butterfly Map → + Track BGLC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BGLC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BGLC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BGLC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGLC)

Health Care Rank #949 of 1016 ⚔️ ADVB vs BGLC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BGLC vs. ADVB, ACON, AMS, SERA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioNexus Gene Lab Corp (BGLC) ranks #949 by composite RQD confidence (30/100, grade E) and #982 by equity capitalization ($2.9M). Within this direct 5-issuer industry benchmark cohort, BGLC leads on earnings valuation at N/A trailing P/E, while ADVB leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. SERA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BGLC at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BGLC ACTIVE BioNexus Gene Lab Corp	E	30/100	—	14.6%	-35.0%	-7.79%	$2.9M	Benchmark Subject
ADVB Advanced Biomed Inc.	E	32/100	—	—	-9.1%	-11.41%	$4.4M	/advb-vs-bglc →
ACON Aclarion Inc.	E	24/100	—	9.0%	-35.0%	-3.43%	$5.7M	/acon-vs-bglc →
AMS American Shared Hospital Services	E	29/100	—	18.0%	-13.8%	-5.26%	$8.4M	/ams-vs-bglc →
SERA Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-bglc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001737523

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioNexus Gene Lab Corp (BGLC) reported GAAP revenue of $7.4M (-21.9% vs. FY2024 revenue of $9.5M , and -24.0% cumulative change since FY2023) , GAAP net income of -$3.0M, operating cash flow of -$1.8M, and free cash flow of -$1.9M (+19.2% YoY). On the balance sheet, BGLC closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.4M	-$3.0M	-$1.8M	-$1.9M	$9.3M	—
FY2024 (FY)	2024-12-31	$9.5M	-$1.6M	-$2.1M	-$2.3M	$10.4M	—
FY2023 (FY)	2023-12-31	$9.8M	-$2.6M	-$1.8M	-$1.8M	—	—

3. BGLC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BGLC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioNexus Gene Lab Corp (NASDAQ: BGLC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.98 (-7.79% 1D, market cap $2.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BGLC ranks #949 in composite RQD confidence.

How does BGLC compare to ADVB and ACON in the Health Care sector?

Within the Health Care sector (Medical Specialities), BGLC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 14.6%, and ROIC of -35.0%. By comparison, ADVB (Advanced Biomed Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -9.1%, cap $4.4M) and ACON (Aclarion Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, BGLC leads on earnings multiple (N/A) while ADVB leads on capital efficiency (-9.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BGLC?

Per BGLC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737523), BioNexus Gene Lab Corp generated $7.4M in revenue (-21.9% YoY), -$3.0M in net income, and -$1.9M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BGLC trading relative to its 50-day, 200-day, and 52-week technical levels?

BGLC last traded at $0.98 (-7.79% on volume of 4,147 shares), positioning the stock -27.41% below its 50-day simple moving average ($1.35) and -50.00% below its 200-day simple moving average ($1.96). Across its 52-week range of $0.88 to $5.67, BGLC sits at the 2.1% percentile with a 14-day RSI of 24.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($1.00 to $1.08).

BGLC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are BGLC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BGLC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: BGLC RQD Cockpit BGLC 12M Forecast BGLC Earnings & Move BGLC Dividends & DRIP BGLC Insiders & 13F BGLC Whale Options BGLC Profit Sankey BGLC News & Why